HMPL-453 not checked

HUTCHMED

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
1 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Cohort\_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort\_2, Cohort\_3 and Cohort\_4:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)”In the company’s words, NCT04353375 on ClinicalTrials.gov
Tested for
Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult
Main trialPhase 2/3
“The goal of this clinical trial is to evaluate in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusion/rearrangement. The main questions it aims to answer are: To evaluate the objective response rate (ORR) of HMPL-453 tartrate in the treatment of patients with advanced intrahepatic cholangiocarcinoma (ICC) habouring fibroblast growth factor receptor (FGFR) 2 fusions/rearrangements after at least one line of systemic treatment failure or intolerance Participants will receive HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Days 1 to 14\] followed by 7…”In the company’s words, NCT04353375 on ClinicalTrials.gov

Other drugs for Solid Tumor, Adult

All 2440 drugs for Solid Tumor, Adult

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 30 Jun 2028 HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Phase 1/2Completed 17 Jul 2025 A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
Phase 1Completed 28 Aug 2023 HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
Phase 1Completed 14 Mar 2025 Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male Subjects
Phase 1Completed 31 Dec 2025 The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate Tablets
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow HMPL-453

Following is part of Solo: you see every change to HMPL-453 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in